
Men who took aspirin over five years slightly lowered their risk for prostate cancer, but women who took low doses over 10 years didn't reduce their risk of cancer, two separate studies indicate.
The conflicting results don’t help settle the debate about whether aspirin and similar anti-inflammatory medicines could be used to prevent cancer. Doctors familiar with the research think different study designs and aspirin doses explain the contrasting findings.
“I don’t think we have a final story on aspirin” and its effects on cancer, said Peter Greenwald, director of cancer prevention at the National Cancer Institute, which helped fund the Women’s Health Study. That study, involving nearly 40,000 women, is among the longest aspirin-cancer studies to date and used doses a little higher than in baby aspirin, taken every other day and compared against dummy pills. It found no effect on lymphoma, colorectal, breast, or several other cancers, although results for lung cancer were less conclusive. Those results contradict several smaller, less rigorous studies that in many cases used higher, more frequent doses.
In the men’s study American Cancer Society researchers followed 70,144 men over nine years and asked about their use of aspirin and other nonsteroidal anti-inflammatory drugs, or NSAIDS, including ibuprofen, such as Advil and Motrin. Men who took standard 325-milligram doses of those medicines daily for at least five years were about 18% less likely to get prostate cancer than men who used aspirin occasionally or for a shorter duration.
That kind of observational study can’t rule out that men who decided to take aspirin were generally healthier and less likely to get cancer to begin with, said Julie Buring of Harvard’s Brigham and Women’s Hospital, lead researcher for the Women’s Health Study. But she said her study can’t rule out whether higher aspirin doses taken daily would protect women against cancer too.
The women’s study appears in Wednesday’s Journal of the American Medical Association. The men’s study is in Wednesday’s Journal of the National Cancer Institute.
Researchers have theorized that aspirin’s anti-inflammatory effects might protect against cancer in which inflammation is thought to play a role, chiefly colorectal cancer but potentially also prostate and breast cancers, said American Cancer Society epidemiologist Eric Jacobs, lead author of the aspirin-prostate cancer study.
Still, Jacobs noted, “The American Cancer Society doesn’t recommend that men or women start taking aspirin or any other NSAIDS to prevent cancer.” They can cause serious side effects, and there’s inadequate evidence about potential cancer-fighting benefits, the cancer society says. (AP)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
Comments that do not concern specific articles in The Advocate or on Advocate.com will not be posted or published. See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.